Shujing Liu

IL8 and Cathepsin B as Melanoma Serum Biomarkers.

Snail1 mediates hypoxia-induced melanoma progression.

Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway.

MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma.

Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation.

Loss of microRNA-205 expression is associated with melanoma progression.

miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion.

Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells.

Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors.

miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.

TR3 is preferentially expressed by bulge epithelial stem cells in human hair follicles.

Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza.

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.

: A Cancer Immunotherapy Review.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.

Loss of Phd2 cooperates with BRAF to drive melanomagenesis.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis.

Multispectral photoacoustic imaging for the detection of subclinical melanoma.

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.

Small extracellular vesicles-based cell-free strategies for therapy.

Targeting regulatory T cells for immunotherapy in melanoma.

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.

HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8 T-cell infiltration into tumors.

Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.

Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity.